公开(公告)号：US20180371089A1

公开(公告)日：2018-12-27

申请号：US16016525

申请日：2018-06-22

Applicant: Development Center for Biotechnology

Inventor： Chia-Cheng WU ,  Tzu-Yin LIN ,  Yu-Jung CHEN ,  Chao-Yang HUANG

IPC: C07K16/28

Abstract: A bispecific anti-Globo H antibody includes an anti-Globo H antibody that binds specifically to Globo H; and a T-cell targeting domain fused to a CH3 domain of a heavy chain of the anti-Globo H antibody, wherein the T-cell targeting domain binds specifically to an antigen on T-cells; and wherein the anti-Globo H antibody comprises mutations at an effector binding site such that the bispecific anti-Globo H antibody has a diminished effector function. The T-cell targeting domain is a ScFv or Fab from an anti-CD3 antibody.

公开(公告)号：US20180186884A1

公开(公告)日：2018-07-05

申请号：US15640935

申请日：2017-07-03

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： JIANN-SHIUN LAI ,  Li-Shuang Ai ,  Yan-Da Lai ,  Yen-Yu Wu ,  Yi-San Tsai ,  Yi-Jiue Tsai ,  Juo-Yu Huang ,  Cheng-Chou Yu ,  Chuan-Lung Hsu ,  Chien-Tsun Kuan ,  Szu-Liang Lai ,  Li-Ya Wang

IPC: C07K16/28 ,  G01N33/74 ,  C07K16/30 ,  A61K51/10 ,  A61K31/4439

CPC classification number: C07K16/2863 ,  A61K31/4439 ,  A61K47/6803 ,  A61K47/6849 ,  A61K51/1027 ,  A61K51/1096 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/71 ,  C07K16/005 ,  C07K16/2818 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/74 ,  G01N2333/71

Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.

公开(公告)号：US09321762B2

公开(公告)日：2016-04-26

申请号：US14103662

申请日：2013-12-11

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Mann-Yan Kuo ,  Chu-Bin Liao ,  Shao-Zheng Peng ,  Shih-Chieh Yen ,  Nan-Horng Lin

IPC: C07D417/14 ,  C07D239/94 ,  C07D401/04 ,  C07D403/04

CPC classification number: C07D417/14 ,  C07D239/94 ,  C07D401/04 ,  C07D403/04

Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein G is a heteroaryl, heterocyclic or alkyne; X is N or CH; L1 is —N(R7)—, —O—, —C(S)—, —C(O)—, or —S—; L2 is —N(R8)— or —O—; R1 and R2 are independently hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxy, C1-C4 alkoxy, C1-C4 alkoxy C1-C4 alkoxy, N,N—(C1-C4 dialkyl)amino C1-C4 alkoxy, N—(C1-C4 alkyl)amino C1-C4 alkoxy, C1-C4 alkanoyl, C1-C4 alkanoyloxy, N—(C1-C4 alkyl)amino, N,N—(C1-C4 dialkyl)amino, C1-C4 alkanoyl amino, or heterocyclyl, wherein C1-C4 alkyl is optionally substituted with one or more substituents selected from fluorine and chlorine; R3, R4 and R5 are independently hydrogen, fluorine or chlorine; R6 is C1-C4 alkyl or aryl, which is optionally substituted with one or more substituents selected from halogen, hydroxyl, amino, cyano, nitro; or R6 and R8 form a 5-6 membered cyclyl or heterocyclyl.

Abstract translation: 一种用于治疗具有式（I）结构的蛋白激酶相关疾病或病症的化合物，其中G是杂芳基，杂环或炔基; X为N或CH; L 1是-N（R 7） - ， - O - ， - C（S） - ， - C（O） - 或-S-; L2是-N（R8） - 或-O-; R1和R2独立地是氢，卤素，羟基，氨基，氰基，硝基，羧基，C1-C4烷氧基，C1-C4烷氧基C1-C4烷氧基，N，N-（C1-C4二烷基）氨基C1-C4烷氧基，N - （C 1 -C 4烷基）氨基C 1 -C 4烷氧基，C 1 -C 4烷酰基，C 1 -C 4烷酰氧基，N-（C 1 -C 4烷基）氨基，N，N-（C 1 -C 4二烷基）氨基，C 1 -C 4烷酰基氨基 或杂环基，其中C 1 -C 4烷基任选被一个或多个选自氟和氯的取代基取代; R3，R4和R5独立地是氢，氟或氯; R6是C1-C4烷基或芳基，其任选被一个或多个选自卤素，羟基，氨基，氰基，硝基的取代基取代; 或R6和R8形成5-6元环基或杂环基。

公开(公告)号：US08999983B2

公开(公告)日：2015-04-07

申请号：US13689590

申请日：2012-11-29

Applicant: Taivex Therapeutics Corporation ,  Development Center for Biotechnology

Inventor： Jiann-Jyh Huang ,  Shih-Hsien Chuang ,  Ying-Shuan Eda Lee ,  Yu-Ling Huang ,  Johnson Lau

IPC: A61K31/5377 ,  C07D417/12 ,  C07D417/14 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07D277/46

CPC classification number: A61K31/5377 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/513 ,  A61K45/06 ,  C07D277/46 ,  C07D417/12 ,  C07D417/14

Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.

Abstract translation: 提供了用于调节Hec1 / Nek2相互作用的化合物，组合物和方法。 这种化合物破坏了Nek2 / Hec1结合，可能作为肿瘤疾病的化学治疗剂。

公开(公告)号：US20140178360A1

公开(公告)日：2014-06-26

申请号：US14192301

申请日：2014-02-27

Applicant: DCB-USA LLC ,  DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Mann-Yan KUO ,  Ying-Shuan Lee ,  Paonien Chen ,  Li Jung Chen ,  Yann Yu Lu ,  Yi-Ting Huang ,  Hung-Yi Hsu ,  Ping-Kuei Tsai

IPC: C07D413/04 ,  A61K31/541 ,  A61K45/06 ,  A61K31/5377 ,  C07D413/14 ,  C07D417/14

CPC classification number: A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07D239/47 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  A61K2300/00

Abstract: The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.

Abstract translation: 本发明涉及式（I）的嘧啶化合物：其可用于治疗mTOR激酶或PI3K激酶相关疾病。